How Ph.D. was paid
$6.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| David Chang, M.D., Ph.D.President and Chief Executive Officer | $724,000 | $1,071,218 | $2,588,329 | $400,010 | $14,217 | $6,136,093 |
| Zachary J. Roberts, M.D., Ph.D.Chief Medical Officer and Executive Vice President of Research and Development | $530,207 | $337,391 | $815,222 | $202,804 | $17,750 | $1,987,723 |
| Geoffrey ParkerExecutive Vice President and Chief Financial Officer | $500,000 | $337,391 | $815,222 | $191,250 | $15,750 | $1,943,962 |
What changed and why
- $6.1M2025 CEO total compensation was $6,136,093, including $2,588,329 in option awards.
- 0%0%: All three named executives received no base-salary increase for 2025.
- 150%150%: 2025 PSU grant-date values reflected maximum possible payout.
- 90.77%90.77%: Stockholders supported the prior year’s say-on-pay proposal, excluding abstentions and broker non-votes.
- 2025 annual incentives were based on achievement of Board-established corporate goals.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.